Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The new mantra for delivering optimal cancer treatment is "personalized care." This extends beyond the holistic to using germline and somatic tumoral mutations to link a specific therapy to some prognostic or predictive factor which defines a particularly responsive patient subgroup who might benefit most from treatment. Furthermore, inherited polymorphisms have the potential to greatly modulate the side effects of treatment, especially for chemotherapy which has a notoriously narrow therapeutic window.

Type

Journal article

Journal

Discov Med

Publication Date

10/2009

Volume

8

Pages

104 - 107

Keywords

Antineoplastic Agents, Biomarkers, Tumor, Colorectal Neoplasms, Genome-Wide Association Study, Genomic Instability, Humans, Pharmacogenetics, Precision Medicine